F2G Ltd, the UK-based antifungal drug discovery and development company, today announced the appointment of John H. Rex, MD, FACP to the position of Chief Medical Officer, effective from 2nd November 2016.
Next generation drug products bring new challenges for analytics and biomanufacture. Tools available for well-established processes are not optimal for next-generation drug products including non-antibody protein drugs, biosimilars and antibody drug conjugates (ADCs). In the article “Advanced Protein Engineering Enhances Biopharmaceutical Manufacturing and Analytics” featured in Bioprocess International’s November 2016 issue, we describe how protein engineering can help develop these urgently needed tools.
The North of England’s top achievers in the life science sector were celebrated on the evening of Thursday 24th November at the 15th annual Bionow awards. Celebrating the crème-de-la-crème of life sciences talent in the North of England and sponsored by Manchester Science Partnerships, the awards ceremony recognised the biomedical industry’s highest achievers.